Business
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
IRVINE, Calif., August 19, 2025--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025.
About this update from Edwards Lifesciences Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/bb4fae29954de4600c681c8279e325a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yiuT3i1TB.bV1Aj6ne7cnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bb4fae29954de4600c681c8279e325a6","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uh.Wp0aHh2HOfjsYz.eXZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/bb4fae29954de4600c681c8279e325a6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"IRVINE, Calif., August 19, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025.","length":320,"tagName":"p"},{"type":"text","content":"Under the terms of this ASR, Edwards will receive an initial delivery of approximately 5 million shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be based on the volume weighted average share price during the term of the agreement. The company is funding the share repurchase under the ASR with its existing cash.","length":367,"tagName":"p"},{"type":"text","content":"Following this repurchase, Edwards has approximately $600 million remaining in its share repurchase authorization approved by its Board of Directors.","length":149,"tagName":"p"},{"type":"text","content":"About Edwards Lifesciences","length":26,"tagName":"p"},{"type":"text","content":"Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.","length":460,"tagName":"p"},{"type":"text","content":"This news release include...